Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies?
The FOURIER trial shows that evolocumab, an injectable monoclonal antibody against PCSK9, decreased the risk of cardiovascular events in high-risk patients receiving statin therapy. The beneficial effects of this drug were consistent with an absolute reduction in LDL cholesterol levels, although stu...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Published: |
Nature Publishing Group
2017
|
| _version_ | 1797065498884571136 |
|---|---|
| author | Preiss, D Baigent, C |
| author_facet | Preiss, D Baigent, C |
| author_sort | Preiss, D |
| collection | OXFORD |
| description | The FOURIER trial shows that evolocumab, an injectable monoclonal antibody against PCSK9, decreased the risk of cardiovascular events in high-risk patients receiving statin therapy. The beneficial effects of this drug were consistent with an absolute reduction in LDL cholesterol levels, although studies with a longer follow-up period are needed. |
| first_indexed | 2024-03-06T21:29:28Z |
| format | Journal article |
| id | oxford-uuid:442e5b03-97e6-4e31-b993-dec5ab3f0302 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T21:29:28Z |
| publishDate | 2017 |
| publisher | Nature Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:442e5b03-97e6-4e31-b993-dec5ab3f03022022-03-26T15:00:04ZCardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies?Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:442e5b03-97e6-4e31-b993-dec5ab3f0302Symplectic Elements at OxfordNature Publishing Group2017Preiss, DBaigent, CThe FOURIER trial shows that evolocumab, an injectable monoclonal antibody against PCSK9, decreased the risk of cardiovascular events in high-risk patients receiving statin therapy. The beneficial effects of this drug were consistent with an absolute reduction in LDL cholesterol levels, although studies with a longer follow-up period are needed. |
| spellingShingle | Preiss, D Baigent, C Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies? |
| title | Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies? |
| title_full | Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies? |
| title_fullStr | Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies? |
| title_full_unstemmed | Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies? |
| title_short | Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies? |
| title_sort | cardiovascular disease pcsk9 inhibition a new player in cholesterol lowering therapies |
| work_keys_str_mv | AT preissd cardiovasculardiseasepcsk9inhibitionanewplayerincholesterolloweringtherapies AT baigentc cardiovasculardiseasepcsk9inhibitionanewplayerincholesterolloweringtherapies |